Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DCY636 · 1 trial · 1 indication
Number of participants with adverse events (AEs) and serious adverse events (SAEs), including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.
Number of participants with adverse events (AEs) and serious adverse events (SAEs), including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.
| Arm | Type | Description |
|---|---|---|
| Part 1- Cohort A1: Dose Level 1 DCY636 | EXPERIMENTAL | Cohort A1: Dose Level 1 DCY636 in healthy participants. |
| Part 1- Cohort A2: Dose Level 2 DCY636 | EXPERIMENTAL | Cohort A2: Dose Level 2 DCY636 in healthy participants. |
| Part 1- Cohort A3: Dose Level 3 DCY636 | EXPERIMENTAL | Cohort A3: Dose Level 3 DCY636 in healthy participants. |
| Part 1- Cohort A4: Dose Level 4 DCY636 | EXPERIMENTAL | Cohort A4: Dose Level 4 DCY636 in healthy participants. |
| Part 1- Cohort B1: Dose Level 5 DCY636 | EXPERIMENTAL | Cohort B1: Dose Level 5 DCY636 in healthy participants. |
| Part 1- Cohort B2: Dose Level 6 DCY636 | EXPERIMENTAL | Cohort B2: Dose Level 6 DCY636 in healthy participants. |
| Part 2- Cohort C1: Dose Level 7 DCY636 | EXPERIMENTAL | Part 2- Cohort C1: Dose Level 7 DCY636 in participants with moderate to severe atopic dermatitis. |
| Part 1- Cohort A1: Placebo | PLACEBO_COMPARATOR | Cohort A1: Placebo in healthy participants. |
| Part 1- Cohort A2: Placebo | PLACEBO_COMPARATOR | Cohort A2: Placebo in healthy participants. |
| Part 1- Cohort A3: Placebo | PLACEBO_COMPARATOR | Cohort A3: Placebo in healthy participants. |
| Part 1- Cohort A4: Placebo | PLACEBO_COMPARATOR | Cohort A4: Placebo in healthy participants. |
| Part 1- Cohort B1: Placebo | PLACEBO_COMPARATOR | Cohort B1: Placebo in healthy participants. |
| Part 1- Cohort B2: Placebo | PLACEBO_COMPARATOR | Cohort B2: Placebo in healthy participants. |
| Part 2- Cohort C1: Placebo | PLACEBO_COMPARATOR | Part 2- Cohort C1: Placebo in participants with moderate to severe atopic dermatitis. |
| Name | Type | Description |
|---|---|---|
| DCY636 | DRUG | Participants will receive DCY636 |
| Placebo | DRUG | Participants will receive Placebo |
Key Inclusion Criteria: Healthy Participants (Part 1) • Healthy male and non-childbearing potential female participants 18 to 55 years of age inclusive. Participants with moderate to severe atopic dermatitis (Part 2) * Males and non-pregnant females age 18 years or older * Diagnosis of atopic de...
DCY636 is an investigational small molecule being developed for the treatment of moderate to severe atopic dermatitis, a form of eczema. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
DCY636 is being developed by Novartis AG, a global pharmaceutical company listed on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
DCY636 is currently in Phase 1 clinical development. It is being studied in a first-in-human trial that includes healthy volunteers and participants with moderate to severe atopic dermatitis. The drug is investigational and has not yet received regulatory approval.
DCY636 is being evaluated in a Phase 1 clinical trial registered as NCT07604324. This first-in-human study is investigating single doses of DCY636 in healthy volunteers and multiple doses in participants with moderate to severe atopic dermatitis. The trial is currently recruiting participants in Japan.
Yes, the Phase 1 clinical trial of DCY636 is a randomized, double-blind, placebo-controlled study. This design helps researchers compare the effects of the drug against a placebo to assess its safety and tolerability in both healthy volunteers and patients with atopic dermatitis.